Genscript Biotech Corporation (GNNSF)
USD 1.25
(0.0%)
USD 1.25
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 417.73 Million USD | 19.42% |
| 2022 | 349.79 Million USD | 123.59% |
| 2021 | 156.45 Million USD | 184.44% |
| 2020 | 55 Million USD | 127.92% |
| 2019 | 24.13 Million USD | 129.79% |
| 2018 | 10.5 Million USD | 848.69% |
| 2017 | 1.1 Million USD | 2206.25% |
| 2016 | 48 Thousand USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 8.17 Million USD | 10.58% |
| 2013 | 7.39 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 877.17 Million USD | 109.98% |
| 2024 Q2 | 877.17 Million USD | 12.77% |
| 2023 Q1 | 872.03 Million USD | 149.29% |
| 2023 Q3 | 833.63 Million USD | 118.87% |
| 2023 Q2 | 380.88 Million USD | -56.32% |
| 2023 FY | 417.73 Million USD | 19.42% |
| 2023 Q4 | 417.73 Million USD | -49.89% |
| 2022 Q4 | 349.79 Million USD | -45.76% |
| 2022 Q3 | 644.91 Million USD | 181.34% |
| 2022 Q2 | 229.23 Million USD | -53.57% |
| 2022 Q1 | 493.76 Million USD | 215.61% |
| 2022 FY | 349.79 Million USD | 123.59% |
| 2021 Q3 | 409.73 Million USD | 634.27% |
| 2021 Q4 | 156.45 Million USD | -61.82% |
| 2021 Q2 | 55.8 Million USD | 9.3% |
| 2021 Q1 | 51.05 Million USD | -7.18% |
| 2021 FY | 156.45 Million USD | 184.44% |
| 2020 Q3 | 52.41 Million USD | -10.42% |
| 2020 FY | 55 Million USD | 127.92% |
| 2020 Q1 | 56.15 Million USD | 132.69% |
| 2020 Q2 | 58.5 Million USD | 4.19% |
| 2020 Q4 | 55 Million USD | 4.94% |
| 2019 Q4 | 24.13 Million USD | 7.91% |
| 2019 Q3 | 22.36 Million USD | -9.4% |
| 2019 Q2 | 24.68 Million USD | 5.93% |
| 2019 Q1 | 23.3 Million USD | 121.88% |
| 2019 FY | 24.13 Million USD | 129.79% |
| 2018 Q3 | 10.5 Million USD | 1635.87% |
| 2018 Q1 | 605 Thousand USD | 0.0% |
| 2018 Q2 | 605 Thousand USD | 0.0% |
| 2018 Q4 | 10.5 Million USD | 0.0% |
| 2018 FY | 10.5 Million USD | 848.69% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | 1.1 Million USD | 2206.25% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | -100.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | 48 Thousand USD | 0.0% |
| 2016 Q2 | 1.23 Million USD | 0.0% |
| 2016 Q1 | 1.23 Million USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 8.17 Million USD | 10.58% |
| 2014 Q4 | 8.17 Million USD | 0.0% |
| 2014 Q3 | 8.17 Million USD | 0.0% |
| 2013 FY | 7.39 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -913.855% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -10034.473% |
| SQZ Biotechnologies Company | 27.47 Million USD | -1420.653% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -863.131% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -1303.355% |
| Mesoblast Limited | 118.7 Million USD | -251.927% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -43952.662% |
| Genus plc | 233.1 Million USD | -79.21% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -14155.403% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -30991.366% |
| Marizyme, Inc. | 18.71 Million USD | -2131.808% |
| ContraFect Corporation | 2.88 Million USD | -14399.778% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -55598.482% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -308223.764% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -28782.883% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -17859.875% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -7282.689% |
| MultiCell Technologies, Inc. | 202.58 USD | -206209110.189% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -626.641% |
| EV Biologics, Inc. | 1.49 Million USD | -27847.037% |
| Q BioMed Inc. | 4.1 Million USD | -10064.004% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -1162.012% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -66199.614% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -33907.805% |
| Biomind Labs Inc. | 735.54 Thousand USD | -56693.306% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | -143.515% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -3114.117% |
| Skye Bioscience, Inc. | 4.61 Million USD | -8951.236% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -46939.247% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -295084.088% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -7015.18% |
| IMV Inc. | 28.88 Million USD | -1346.268% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -1624141.292% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -18397.261% |
| GB Sciences, Inc. | 1.75 Million USD | -23644.498% |
| Alpha Cognition Inc. | 1.22 Million USD | -34130.433% |
| HST Global, Inc. | 98.31 Thousand USD | -424780.865% |
| CSL Limited | 12.18 Billion USD | 96.571% |
| Halberd Corporation | 150 Thousand USD | -278392.412% |
| Enzolytics Inc. | 996.33 Thousand USD | -41827.4% |
| Resverlogix Corp. | 6.49 Million USD | -6335.659% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -87384.527% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -163339.63% |
| argenx SE | 20 Million USD | -1988.693% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -816.898% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -15322.09% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -4085363.257% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -208127.967% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -17322.298% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -182087.098% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -517.565% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -13704.106% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -116032.056% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -1954.991% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -280914.045% |
| BioStem Technologies, Inc. | 4.71 Million USD | -8766.518% |
| ONE Bio Corp. | 19.71 Million USD | -2018.885% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -166873.89% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -167855.379% |
| Agentix Corp. | 50 Thousand USD | -835377.236% |
| LadRx Corporation | 33.6 Thousand USD | -1242947.724% |
| Cell Source, Inc. | 9.25 Million USD | -4414.056% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -55141.525% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -55141.525% |
| NovAccess Global Inc. | 2.19 Million USD | -18889.155% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -5806.261% |
| Itoco Inc. | 228.37 Thousand USD | -182816.239% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -197903.848% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -8283.275% |
| Kadimastem Ltd | 891.22 Thousand USD | -46772.355% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -103854.127% |
| CytoDyn Inc. | 30.07 Million USD | -1288.943% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -86159.017% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -118627.35% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -5241.953% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -340911.117% |
| Rebus Holdings, Inc. | 310 Thousand USD | -134654.393% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -8721.832% |
| International Stem Cell Corporation | 4.17 Million USD | -9898.531% |
| Bioxytran, Inc. | 1.92 Million USD | -21600.707% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -669213.473% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -19054.414% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -4923.312% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -4765.913% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -26755.947% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -155772.619% |
| Neutra Corp. | 54.15 Thousand USD | -771261.655% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -22727.247% |
| PureTech Health plc | 25.51 Million USD | -1537.42% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -34022.672% |
| IXICO plc | 472.02 Thousand USD | -88399.632% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -2594.914% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -570.926% |
| CSL Limited | 12.18 Billion USD | 96.571% |
| Cellectis S.A. | 92.77 Million USD | -350.263% |